Diagnostic utility of telomere length testing in a hospital-based setting

JK Alder, VS Hanumanthu, MA Strong… - Proceedings of the …, 2018 - National Acad Sciences
JK Alder, VS Hanumanthu, MA Strong, AE DeZern, SE Stanley, CM Takemoto, L Danilova
Proceedings of the National Academy of Sciences, 2018National Acad Sciences
Telomere length (TL) predicts the onset of cellular senescence in vitro but the diagnostic
utility of TL measurement in clinical settings is not fully known. We tested the value of TL
measurement by flow cytometry and FISH (flowFISH) in patients with mutations in
telomerase and telomere maintenance genes. TL had a discrete and reproducible normal
range with definable upper and lower boundaries. While TL above the 50th age-adjusted
percentile had a 100% negative predictive value for clinically relevant mutations, the lower …
Telomere length (TL) predicts the onset of cellular senescence in vitro but the diagnostic utility of TL measurement in clinical settings is not fully known. We tested the value of TL measurement by flow cytometry and FISH (flowFISH) in patients with mutations in telomerase and telomere maintenance genes. TL had a discrete and reproducible normal range with definable upper and lower boundaries. While TL above the 50th age-adjusted percentile had a 100% negative predictive value for clinically relevant mutations, the lower threshold in mutation carriers was age-dependent, and adult mutation carriers often overlapped with the lowest decile of controls. The extent of telomere shortening correlated with the age at diagnosis as well as the short telomere syndrome phenotype. Extremely short TL caused bone marrow failure and immunodeficiency in children and young adults, while milder defects manifested as pulmonary fibrosis-emphysema in adults. We prospectively examined whether TL altered treatment decisions for newly diagnosed idiopathic bone marrow failure patients and found abnormally short TL enriched for patients with mutations in some inherited bone marrow failure genes, such as RUNX1, in addition to telomerase and telomere maintenance genes. The result was actionable, altering the choice of treatment regimen and/or hematopoietic stem cell donor in one-fourth of the cases (9 of 38, 24%). We conclude that TL measurement by flowFISH, when used for targeted clinical indications and in limited settings, can influence treatment decisions in ways that improve outcome.
National Acad Sciences